The FSHD Society is holding a landmark meeting today in which individuals and families living with facioscapulohumeral muscular dystrophy (FSHD) will tell representatives from the U.S. Food and Drug Administration […]
Facioscapulohumeral muscular dystrophy community speaks to the FDA
Genetic Cause
[…] two distinct genetic mechanisms. The most common, found in 95 percent or patients, is called FSHD Type 1, or FSHD1. The remaining 5 percent is called FSHD Type 2 (FSHD2), […]
Celebrating Moms
[…] approaching, we would like to take a moment to celebrate the amazing moms in the FSHD Community. Being a mother is learning about strengths you didn’t know you had, and […]
The challenges of the new era
[…] new era in clinical trials, what do we mean? After all, we have seen previous FSHD trials, including those by Wyeth, aTyr, Acceleron, and Fulcrum’s ReDUX4. What makes the current […]
Home
Ensuring no one faces Facioscapulohumeral Muscular Dystrophy ( FSHD) alone. Our goal for all impacted by FSHD is two-fold: 1) Speed the delivery of effective treatments and a cure and; […]